News & Updates
Filter by Specialty:
Triplet therapy with ARSI, docetaxel, ADT boosts survival in mHSPC
Adding androgen receptor signaling inhibitors (ARSI) to a treatment regimen consisting of docetaxel and androgen deprivation therapy (ADT) can lead to better survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to a recent meta-analysis.
Triplet therapy with ARSI, docetaxel, ADT boosts survival in mHSPC
05 Sep 2022
Chemoablative gel preferrable over surgery in adults with nonmuscle-invasive bladder cancer
UGN-102, a nonsurgical, chemoablative gel used as a primary treatment for nonmuscle-invasive bladder cancer (NMIBC), is more patient-centred than standard treatments, according to a recent study.
Chemoablative gel preferrable over surgery in adults with nonmuscle-invasive bladder cancer
01 Sep 2022
Do multivitamins increase prostate cancer risk in older men?
Taking multivitamins regularly or for a long duration neither heightens nor reduces the risk of overall or aggressive prostate cancer among older, generally well-nourished men, results of a study have shown.
Do multivitamins increase prostate cancer risk in older men?
31 Aug 2022
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.
